Navigation Links
AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
Date:2/29/2008

QUEBEC CITY, Feb. 29 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced the resignation of Mario Paradis, CA, the Company's Senior Vice President, Administrative & Legal Affairs and Corporate Secretary. Mr. Paradis has accepted the position of Vice President and Chief Financial Officer of Atrium Innovations, a leading developer, manufacturer and marketer of science-based products for the cosmetics, pharmaceutical, chemical and nutrition industries. Mr. Paradis will remain in his capacity at the Company through a transition period, and his departure will become effective in early April.

David J. Mazzo, Ph.D., President and CEO of AEterna Zentaris commented, "We would like to extend our sincere appreciation to Mario for his dedication and significant contributions to the evolution of AEterna Zentaris over the years. We wish him well as he embarks on this new chapter in his career."

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology with proven expertise in drug discovery, development and commercialization.
News releases and additional information are available at http://www.aezsinc.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Suc
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
2. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
3. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Announces Outcome of Managements Strategic Review
6. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
7. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
8. Exelixis Announces March 4 Webcast of Presentation at the Susquehanna SIGnificant Options in Healthcare Conference
9. MarketResearch.com Announces Distribution of Spectra Intelligence Research
10. Kosan Announces Senior Management Changes and Clinical Portfolio Priorities
11. Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)... Ambassador to also Visit Detroit , ...David Appia, French Ambassador for International I...rance Agency, , , , ,What: Ambassador Appia is av...usiness initiatives adopted by France to further d...e for innovation and development., , ,When: Availa...
(Date:11/24/2009)...RNewswire-FirstCall/--Sigma-AldrichCorporation(Nas...eonTuesday,December1stat1:45PMGMTinLondon,7:45AMUS...stovertheInternetavailableat http://inve s tor....st"icontoaccessthisfile. ,, AboutSigma-Aldric...ologycompany.Itschemicalandbiochemicalproductsandk...
(Date:11/24/2009)...RNewswire-Asia/--ShanghaiBiolaxyannouncedthe,Chine...dthe,investigationalnewdrugapplication(IND)foritso...ulationtotreatdiabetes.ThisIND,approvalallowsBiola...abetesisadisordercharacteristicofhighbloodglucosea...esultinseveremicro-and,macro-vasculardiseases,loss...
(Date:11/24/2009).../PRNewswire-FirstCall/--Shireplc(LSE:SHP,NASDAQ: ...,today,announcedthatithassubmittedaMAAtotheEuropea...enzymereplacementtherapyindevelopment,forthetreatm...pplicationforvelaglucerasealfathathasbeensubmitted...a. , Basedonaglobalsupplyshortageofthecurrent...
Breaking Biology Technology:Biolaxy Secures IND Approval for Oral Insulin 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3
...C., April 2 Chimerix, Inc., a biotechnology compa...ics, announced today that the Company has joined t...work of public-private partnerships to discover, d...ve and affordable antimalarial drugs. The MMV will...ivity against malaria, and any lead candidates tha...
...lution A/S today announced that Merck & Co. In...e collaboration agreement announced in June 2008 t...g discovery technology to identify novel small mol...entering the second phase, Merck gains access to a...mall molecule drug candidates. In addition, this ...
... /PRNewswire-Asia-FirstCall/ -- China Biologic,Pro...logic" or the "Company"),one of the leading plasma...public of China ("PRC"), reported financial result...8 Highlights, -- Revenues increased 44.3% year-...rofit increased 45.7% to $32.7 million over 2007, ...
Other Biology Technology:Chimerix Joins International Network of Organizations to Cure Malaria 2Chimerix Joins International Network of Organizations to Cure Malaria 3Nuevolution Announces Progress in Its Collaboration With Merck & Co. Inc. 2China Biologic Products Announces Strong 2008 Results 2China Biologic Products Announces Strong 2008 Results 3China Biologic Products Announces Strong 2008 Results 4China Biologic Products Announces Strong 2008 Results 5China Biologic Products Announces Strong 2008 Results 6China Biologic Products Announces Strong 2008 Results 7China Biologic Products Announces Strong 2008 Results 8China Biologic Products Announces Strong 2008 Results 9China Biologic Products Announces Strong 2008 Results 10China Biologic Products Announces Strong 2008 Results 11China Biologic Products Announces Strong 2008 Results 12China Biologic Products Announces Strong 2008 Results 13China Biologic Products Announces Strong 2008 Results 14China Biologic Products Announces Strong 2008 Results 15
(Date:11/24/2009)...ambridge, Md. (November 24, 2009) New research on... river ecosystems reveals predictable temporal pat...communities as markers for monitoring climate chan... week in the Proceedings of the National Academy ...ommunities in the six rivers shifted synchronously...
(Date:11/23/2009)... TORONTO, November 23, 2009 - The time of day matt...g to a new paper produced by a research team led b...o Scarborough,s vice-principal for research and co...logy at the St. George campus. , Capitalizing ... poplar tree, the research team examined how popla...
(Date:11/23/2009)... AMES, Iowa - The only swine vaccine available for... herd infected with the virus. The vaccination mar... herd diagnosed with the pandemic flu., Iowa Sta...cience, developed the vaccine this summer and has ...in Iowa, Kansas and Illinois for several weeks., ...
Breaking Biology News(10 mins):Researchers establish common seasonal pattern among bacterial communities in Arctic rivers 2Time of day matters to thirsty trees, U of T researcher discovers 2Iowa State researcher produces, ships only H1N1 vaccine available for swine 2Glucose metabolism and recidivism of severe violent crimes in alcohol intoxications 47468 1Glucose metabolism and recidivism of severe violent crimes in alcohol intoxications 47468 2New study finds lowfat chocolate milk is effective post exercise recovery aid for soccer players 8670 1New study finds lowfat chocolate milk is effective post exercise recovery aid for soccer players 8670 2Survey Reveals Injectable Procedures Are Mainstream And Accepted Medical Aesthetic Treatment Options 47464 1Survey Reveals Injectable Procedures Are Mainstream And Accepted Medical Aesthetic Treatment Options 47464 2Survey Reveals Injectable Procedures Are Mainstream And Accepted Medical Aesthetic Treatment Options 47464 3Survey Reveals Injectable Procedures Are Mainstream And Accepted Medical Aesthetic Treatment Options 47464 4
...at the University of Massachusetts Medical School ...es the ability of scientists to target individual ...tial implications for both basic science research ...ne led by Scot A. Wolfe, PhD, an assistant profess...d the Department of Biochemistry & Molecular Pharm...
...ity Medical Centre (LUMC) are the first to determi...rst European whose DNA sequence has been determine... morning, during a special press conference at Bes...ss in the Netherlands. , Following in-depth ana...cidental privacy-sensitive findings. The results w...
...e discovered a new strategy for an immunization ag...d that immune cells react strongly to the modified...ect has occurred. It is estimated that this repair...rs. , The researchers, led by Professor Dr. Mag...Department of Applied Tumor Biology at the Heidelb...
Other Biology News:New technique allows targeted inactivation of genes in research model 2Leiden scientists sequence first female DNA 2To fight the cancer before the tumor grows 2
ImageQuant 400 from GE Healthcare, formerly Amersham Biosciences
IMAGEQUANT 100 WKSTN from GE Healthcare, formerly Amersham Biosciences
Cathepsin L Fluorometric (cresyl violet) Assay Kit, Magic Red from AbD Serotec
ImageQuant 300 from GE Healthcare, formerly Amersham Biosciences
Biology Products: